Some people have tried three antidepressants. Five. Seven. And still haven’t found meaningful relief. That’s treatment-resistant depression (TRD), and an estimated 4 million Americans are living with it. Today, for the first time, it has its own awareness day.

Amast Health built a Spravato practice from scratch, but operations consumed precious time. "The things that we didn't have a plan for yet were the things that Osmind was gonna take care of."

For two years, Sahab Yaqubi, M.D. ran his EHR in one system and his billing in another, connected by a clearinghouse and a shared folder. "The problem was that there were several systems. Here it's all one."

That's a wrap on back-to-back conferences: Behavioral Health Tech in Nashville and ASKP³ Mastering the Essentials in Denver. Thank you to everyone who stopped by our booth and to the speakers who sharpened our thinking.

What breaks when your interventional psychiatry practice grows faster than the systems supporting it? More inquiries can mean more missed follow-ups. More referrals can leave teams chasing the next step. More capacity can sit unused while the same bottlenecks keep people from starting treatment.

We’re honored to have TIME recognize Osmind as one of the World's Top Health Tech Companies of 2026!

You know the patient who arrives with a coping strategy that was adaptive at twenty-four and calcified into a constraint at thirty-four? Your psychiatry practice can do the same thing. See the six places that gap costs practices money, and how to fix it: www.osmind.org/blog/where-i...

Where Is Your Psychiatry Practice Losing Revenue? (And how to fix it) | Osmind

See where interventional psychiatry practices lose revenue, time, and capacity, and how to diagnose gaps in collections, A/R, billing, and operations.

osmind.org

“Interventional psychiatry” has been part of the field’s vocabulary for years, but there has never been a formal definition of what it really means.

If COMP360 is approved, what will it actually take for a clinic to deliver psilocybin treatment safely? Join Stephanie Knatz Peck, Ph.D. (Co-Founder and CCO, Strata Mental Health) for a 30-minute conversation in the Psychiatry Collective on what site readiness really looks like.

"More is better" might be the most expensive reflex in interventional psychiatry. More TMS pulses. More frequent ketamine. Higher doses for the sickest patients.

Join us for Q’s with Koo, a live event hosted by Dr. Martha Koo and members of the Psychiatry Collective as we explore what’s new in interventional psychiatry, from practice tips to clinical considerations. 🗓️When: Thursday, Aug 27, 11:00 AM - 11:30 AM PDT / 2 - 2:30 PM ET

Before you add another provider, machine, or location, answer one question: Can you see where patients are falling through the cracks?

200 miles from the nearest major city, Cassandra Heuer opened her psychiatry practice, Elevate Wellness & Psychiatry in her hometown of 14,000 people.

Osmind is partnering with Tasman Therapeutics to accelerate the development and commercialization of innovative treatments for neuropsychiatric disorders.

Scale doesn’t ‘fix’ a clinic’s growth system; It multiplies whatever’s already working or broken. For interventional psychiatry practices, growth puts more pressure on every handoff between patient interest and completed treatment.

Get dedicated COMP360 resources. Prepare your practice for psychedelics. Get Access to the resource vault by filling out a 1-minute survey (link in comments →)

he FDA approved Viagra in 1998. It took another 17 years to approve the first drug for low sexual desire in premenopausal women, and Anita Clayton, MD, spent much of that time challenging how medicine studied women’s sexual health. New Psychiatry Tomorrow podcast!: www.osmind.org/blog/antidep...

Antidepressant Sexual Dysfunction and Women's Health with Anita Clayton, MD | Osmind

Anita Clayton, MD, built the scale for measuring antidepressant sexual dysfunction. She made psychiatry pay attention to women's sexcual health, and was featured in the documentary "The Little Pink Pi...

osmind.org

Less than 1% of the people who'd qualify for TMS ever get it. Scott West brought TMS to Tennessee in 2010. Fifteen years later, he says the problem is awareness.

We'll be at the APA Annual Meeting in San Francisco later this week. Here's where to find us:

As we gear up for the American Psychiatric Association (APA) Annual Meeting in our home base of San Francisco, we’re proud to share that our latest research in collaboration with the APA on the DSM-5 Cross-Cutting Symptom Measure has been published in Frontiers in Psychiatry.

Free credentialing for a limited time.

Looking to lower your SPRAVATO® drug costs and streamline your practice operations? Join our monthly SPRAVATO® office hours hosted live inside the Psychiatry Collective on May 5th at 9 am PT / 12 pm ET.

Osmind is proud to collaborate with Compass Pathways to help independent psychiatry practices prepare for the potential future delivery of psychedelic medicine.

Saturday's executive order clears federal roadblocks that have slowed psychedelic treatments for decades. But approval (if and when it comes) doesn't equal access.

Osmind partnered with CareNet GPO. Through this partnership, practices get negotiated savings on specialty medications starting with Spravato®, a community of peers sharing what works across buy-and-bill, inventory management, and operations, and resources to help your practice grow sustainably.

Treatment-resistant depression doesn't have a formal DSM definition. But most psychiatrists know it when they see it—and most of them are seeing it constantly. Watch: Psychiatric Times panel to see why depression persists after multiple medication trials, and what full remission actually requires.

Eli Lilly just launched Phase 3 trials for a GLP-1 drug in alcohol use disorder. Not diabetes. Not weight loss. Addiction. What psychiatrists need to know: www.osmind.org/blog/glp-1-p...

GLP-1 Agonists Are Psychiatric Drugs. Psychiatry Should Start Acting Like It | Osmind

Are GLP-1 agonists psychiatric drugs? The neuroscience of reward, new addiction trial data, and a dosing hypothesis that reframes anhedonia.

osmind.org

Five years ago, Benjamin Leopold was curled on his apartment floor with a bottle of scotch. Today he runs marathons, writes horror novels, and surfs whenever he can get to the coast. SPRAVATO® (esketamine) gave a bird’s eye view to years of trauma. www.osmind.org/blog/spravat...

How SPRAVATO® (esketamine) Helped Ben Finally See Himself Clearly | Osmind

Hear how one Spravato patient went from cycling through 10 antidepressants to building a life he loves — running marathons, writing novels, and surfing. Ben Leopold shares how the combination of deep ...

osmind.org

For psychiatrists looking to help treatment-resistant patients while adding a profitable service line, TMS is worth a serious look. www.osmind.org/blog/guide-t...

Guide to Adding TMS to Your Psychiatric Practice | Osmind

Ready to add TMS to your practice? This guide covers patient eligibility, 2026 device pricing for 8 systems, financing, billing codes, and how to build your referral pipeline from day one.

osmind.org

our patients started a GLP-1 for weight loss. Then they stopped drinking. Then they quit smoking. Then the compulsive shopping slowed down. Sound familiar? You're not alone. This is just one of the conversations happening right now inside the Psychiatry Collective.